Galectin Therapeutics Inc.

NASDAQ:GALT

Biotechnology

Healthcare
$2.98 +1.62%

+$0.05 today

Market cap
$196.25M
Beta
0.49
P/E (TTM)
-7.1
EPS (TTM)
-$0.40
52W Low $1.85High $7.13

Volume 0.23M

Average 0.32M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$20.09M

FY 2025 · Annual

Net Income

-$30.84M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development23.82M31.74M32.13M36.57M14.29M
Selling, General & Admin6.36M6.62M5.94M5.86M5.8M
Operating Expenses30.18M38.35M38.07M42.43M20.09M
Depreciation & Amortization41K32K33K37K53K
EBITDA(30M)(37.71M)(38.24M)(41.47M)(23.45M)
EBITDA Margin—————
Operating Income(30.18M)(38.35M)(38.07M)(42.43M)(20.09M)
Operating Margin—————
Interest Income3K52K230K338K126K
Interest Expense489K1.03M2.79M5.54M7.33M
Other Income / Expenses(348K)(424K)(2.99M)(4.61M)(10.75M)
Income Before Tax(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(30.53M)(38.78M)(41.07M)(47.05M)(30.84M)
Net Margin—————
EPS (Basic)(0.52)(0.65)(0.74)(0.76)(0.48)
EPS (Diluted)(0.52)(0.65)(0.74)(0.76)(0.48)
Weighted Avg Shares58.53M59.39M60.16M62.31M63.9M
Weighted Avg Shares (Diluted)58.53M59.39M60.16M62.31M63.9M

GALT Earnings Waterfall · TTM

NASDAQ:GALT · Revenue to Net Income

Key Ratios

EPS$-0.41
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-8.5
P/S Ratio0.0

Analysis

$0 of revenue converted into -$26.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.41, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
ARSARS filingOct 13, 2026
DEF 14ADEF 14A filingOct 13, 2026
DEFA14ADEFA14A filingOct 13, 2026
PRE 14APRE 14A filingOct 2, 2026
10-QQuarterly reportAug 14, 2026

How much revenue does GALT generate?

Galectin Therapeutics Inc. (GALT) reported $0.00 of revenue in fiscal 2025.

Is GALT profitable?

Galectin Therapeutics Inc. (GALT) reported -$30.84M of net income.